1667TiP Durvalumab plus platinum-etoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): A Spanish phase IIIb single arm, real-world study

Abstract

Small cell lung cancer (SCLC) represents approximately 13% of all newly diagnosed lung cancers. Most patients have extensive-stage (ES) disease at diagnosis, and prognosis remains poor, with a 5-year survival less than 2% despite receiving the standard of care: four to six cycles of etoposide (ET) in combination with either cisplatin (CPT) or carboplatin (CP) (platinum (PT) –etoposide). CASPIAN trial showed that durvalumab (D) in combination with PT-ET in treatment-naive patients with ES-SCLC improved overall survival.